<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35337143</PMID><DateRevised><Year>2022</Year><Month>03</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1424-8247</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Mar</Month><Day>11</Day></PubDate></JournalIssue><Title>Pharmaceuticals (Basel, Switzerland)</Title><ISOAbbreviation>Pharmaceuticals (Basel)</ISOAbbreviation></Journal><ArticleTitle>Efficacy of Adaptogens in Patients with Long COVID-19: A Randomized, Quadruple-Blind, Placebo-Controlled Trial.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">345</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ph15030345</ELocationID><Abstract><AbstractText>Currently, no effective treatment of comorbid complications or COVID-19 long-haulers during convalescence is known. This randomized, quadruple-blind, placebo-controlled trial aimed to assess the efficacy of adaptogens on the recovery of patients with Long COVID symptoms. One hundred patients with confirmed positive SARS-CoV-2 test, discharged from COVID Hotel isolation, Intensive Care Unit (ICU), or Online Clinics, and who experienced at least three of nine Long COVID symptoms (fatigue, headache, respiratory insufficiency, cognitive performance, mood disorders, loss of smell, taste, and hair, sweatiness, cough, pain in joints, muscles, and chest) in the 30 days before randomization were included in the study of the efficacy of Chisan<sup>&#xae;</sup>/ADAPT-232 (a fixed combination of adaptogens Rhodiola, Eleutherococcus, and Schisandra) supplementation for two weeks. Chisan<sup>&#xae;</sup> decreased the duration of fatigue and pain for one and two days, respectively, in 50% of patients. The number of patients with lack of fatigue and pain symptoms was significantly less in the Chisan<sup>&#xae;</sup> treatment group than in the placebo group on Days 9 (39% vs. 57%, pain relief, <i>p</i> = 0.0019) and 11 (28% vs. 43%, relief of fatigue, * <i>p</i> = 0.0157). Significant relief of severity of all Long COVID symptoms over the time of treatment and the follow-up period was observed in both groups of patients, notably decreasing the level of anxiety and depression from mild and moderate to normal, as well as increasing cognitive performance in patients in the d2 test for attention and increasing their physical activity and workout (daily walk time). However, the significant difference between placebo and Chisan<sup>&#xae;</sup> treatment was observed only with a workout (daily walk time) and relieving respiratory insufficiency (cough). A clinical assessment of blood markers of the inflammatory response (C-reactive protein) and blood coagulation (D-dimer) did not reveal any significant difference over time between treatment groups except significantly lower IL-6 in the Chisan<sup>&#xae;</sup> treatment group. Furthermore, a significant difference between the placebo and Chisan<sup>&#xae;</sup> treatment was observed for creatinine: Chisan<sup>&#xae;</sup> significantly decreased blood creatinine compared to the placebo, suggesting prevention of renal failure progression in Long COVID. In this study, we, for the first time, demonstrate that adaptogens can increase physical performance in Long COVID and reduce the duration of fatigue and chronic pain. It also suggests that Chisan<sup>&#xae;</sup>/ADAPT-232 might be useful for preventing the progression of renal failure associated with increasing creatinine.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Karosanidze</LastName><ForeName>Irina</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>National Family Medicine Training Centre, 57 M. Tsinamdzghvrishvili Str., Tbilisi 0102, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiladze</LastName><ForeName>Ushangi</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>National Family Medicine Training Centre, 57 M. Tsinamdzghvrishvili Str., Tbilisi 0102, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirtadze</LastName><ForeName>Nino</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>National Family Medicine Training Centre, 57 M. Tsinamdzghvrishvili Str., Tbilisi 0102, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giorgadze</LastName><ForeName>Mikhail</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>National Family Medicine Training Centre, 57 M. Tsinamdzghvrishvili Str., Tbilisi 0102, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amashukeli</LastName><ForeName>Nana</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>National Family Medicine Training Centre, 57 M. Tsinamdzghvrishvili Str., Tbilisi 0102, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parulava</LastName><ForeName>Nino</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>National Family Medicine Training Centre, 57 M. Tsinamdzghvrishvili Str., Tbilisi 0102, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iluridze</LastName><ForeName>Neli</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>National Family Medicine Training Centre, 57 M. Tsinamdzghvrishvili Str., Tbilisi 0102, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kikabidze</LastName><ForeName>Nana</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>National Family Medicine Training Centre, 57 M. Tsinamdzghvrishvili Str., Tbilisi 0102, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gudavadze</LastName><ForeName>Nana</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>National Family Medicine Training Centre, 57 M. Tsinamdzghvrishvili Str., Tbilisi 0102, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gelashvili</LastName><ForeName>Lali</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>National Family Medicine Training Centre, 57 M. Tsinamdzghvrishvili Str., Tbilisi 0102, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koberidze</LastName><ForeName>Vazha</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>National Family Medicine Training Centre, 57 M. Tsinamdzghvrishvili Str., Tbilisi 0102, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gigashvili</LastName><ForeName>Eka</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>National Family Medicine Training Centre, 57 M. Tsinamdzghvrishvili Str., Tbilisi 0102, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jajanidze</LastName><ForeName>Natela</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>National Family Medicine Training Centre, 57 M. Tsinamdzghvrishvili Str., Tbilisi 0102, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Latsabidze</LastName><ForeName>Naira</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>National Family Medicine Training Centre, 57 M. Tsinamdzghvrishvili Str., Tbilisi 0102, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mamageishvili</LastName><ForeName>Nato</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department for History of Medicine and Bioethics, Faculty of Medicine, Tbilisi State Medical University, Vazha-Pshavela Ave. 33, Tbilisi 0162, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shengelia</LastName><ForeName>Ramaz</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department for History of Medicine and Bioethics, Faculty of Medicine, Tbilisi State Medical University, Vazha-Pshavela Ave. 33, Tbilisi 0162, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hovhannisyan</LastName><ForeName>Areg</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Fine Organic Chemistry, National Academy of Science, Azatutian ave. 26, Yerevan 375014, Armenia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panossian</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8467-4525</Identifier><AffiliationInfo><Affiliation>Phytomed AB, Bofinksvagen 1, 31275 V&#xe5;xtorp, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Nr 2021-2</GrantID><Agency>Swedish Herbal Institute R&amp;amp;D in Vallberga</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pharmaceuticals (Basel)</MedlineTA><NlmUniqueID>101238453</NlmUniqueID><ISSNLinking>1424-8247</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">C-reactive protein</Keyword><Keyword MajorTopicYN="N">Chisan&#xae;/ADAPT-232</Keyword><Keyword MajorTopicYN="N">D-dimer</Keyword><Keyword MajorTopicYN="N">IL-6</Keyword><Keyword MajorTopicYN="N">adaptogens</Keyword><Keyword MajorTopicYN="N">clinical trial</Keyword><Keyword MajorTopicYN="N">creatinine</Keyword><Keyword MajorTopicYN="N">long COVID-19 symptoms</Keyword><Keyword MajorTopicYN="N">physical performance</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest. A.P. is self-employed at the research and development company Phytomed AB and has no shares or financial interest in any pharmaceutical company. The funders had no role in the study&#x2019;s design, in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>26</Day><Hour>1</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>3</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35337143</ArticleId><ArticleId IdType="pmc">PMC8953947</ArticleId><ArticleId IdType="doi">10.3390/ph15030345</ArticleId><ArticleId IdType="pii">ph15030345</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>De Graaf M.A., Antoni M.L., Ter Kuile M.M., Arbous M.S., Duinisveld A.J.F., Feltkamp M.C.W., Groeneveld G.H., Hinnen S.C.H., Janssen V.R., Lijfering W.M., et al. Short-term outpatient follow-up of COVID-19 patients: A multidisciplinary approach. eClinicalMedicine. 2021;32:100731. doi: 10.1016/j.eclinm.2021.100731.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.100731</ArticleId><ArticleId IdType="pmc">PMC7843037</ArticleId><ArticleId IdType="pubmed">33532720</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S., Wegman-Ostrosky T., Perelman C., Sepulveda R., Rebolledo P.A., Cuapio A., Villapol S. More than 50 Long-term effects of COVID-19: A systematic review and meta-analysis.  [(accessed on 14 February 2022)];medRxiv. 2021  doi: 10.1101/2021.01.27.21250617. the preprint server for health sciences. Available online:  https://www.nature.com/articles/s41598-021-95565-8.pdf.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.27.21250617</ArticleId><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde M.W., Kim S.S., Lindsell C.J., Billig Rose E., Shapiro N.I., Files D.C., Gibbs K.W., Erickson H.L., Steingrub J.S., Smithline H.A., et al. CDC COVID-19 Response Team, IVY Network Investigators. Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network&#x2014;United States, March&#x2013;June 2020. MMWR Morb. Mort. Wkly. Rep. 2020;69:993&#x2013;998. doi: 10.15585/mmwr.mm6930e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6930e1</ArticleId><ArticleId IdType="pmc">PMC7392393</ArticleId><ArticleId IdType="pubmed">32730238</ArticleId></ArticleIdList></Reference><Reference><Citation>Callard F., Perego E. How and why patients made Long COVID. Soc. Sci. Med. 2021;268:113426. doi: 10.1016/j.socscimed.2020.113426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.socscimed.2020.113426</ArticleId><ArticleId IdType="pmc">PMC7539940</ArticleId><ArticleId IdType="pubmed">33199035</ArticleId></ArticleIdList></Reference><Reference><Citation>Go&#xeb;rtz Y., Van Herck M., Delbressine J.M., Vaes A.W., Meys R., Machado F., Houben-Wilke S., Burtin C., Posthuma R., Franssen F., et al. Persistent symptoms 3&#x2005;months after a SARS-CoV-2 infection: The post-COVID-19 syndrome? ERJ Open Res. 2020;6:00542-2020. doi: 10.1183/23120541.00542-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/23120541.00542-2020</ArticleId><ArticleId IdType="pmc">PMC7491255</ArticleId><ArticleId IdType="pubmed">33257910</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J.P., Chesney E., Oliver D., Pollak T.A., McGuire P., Fusar-Poli P., Zandi M.S., Lewis G., David A.S. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: A systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020;7:611&#x2013;627. doi: 10.1016/S2215-0366(20)30203-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(20)30203-0</ArticleId><ArticleId IdType="pmc">PMC7234781</ArticleId><ArticleId IdType="pubmed">32437679</ArticleId></ArticleIdList></Reference><Reference><Citation>ClinicalTrials.gov  Long COVID.  [(accessed on 14 February 2022)]; Available online:  https://clinicaltrials.gov/ct2/results?term=Long+COVID&amp;cond=COVID-19&amp;age_v=&amp;gndr=&amp;type=Intr&amp;rslt=&amp;Search=Apply.</Citation></Reference><Reference><Citation>ClinicalTrials.gov  COVID-19 Long-Haulers Study.  [(accessed on 14 February 2022)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT04678830.</Citation></Reference><Reference><Citation>ClinicalTrials.gov  Zilucoplan&#xae; in Improving Oxygenation and Short- and Long-Term Outcome of COVID-19 Patients with Acute Hypoxic Respiratory Failure.  [(accessed on 14 February 2022)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT04382755.</Citation></Reference><Reference><Citation>ClinicalTrials.gov  WHO COVID-19&#x2014;Evaluation of the Efficacy of Probiotics to Reduce the Occurrence of Long COVID.  [(accessed on 14 February 2022)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT05080244.</Citation></Reference><Reference><Citation>ClinicalTrials.gov  Phase 2 Study of RSLV-132 in Subjects with Long COVID.  [(accessed on 14 February 2022)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT04944121.</Citation></Reference><Reference><Citation>ClinicalTrials.gov  Homeopathic Treatment of Post-Acute COVID-19 Syndrome.  [(accessed on 14 February 2022)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT05104749.</Citation></Reference><Reference><Citation>ClinicalTrials.gov  Feasibility of Cannabidiol for the Treatment of Long COVID.  [(accessed on 14 February 2022)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT04997395.</Citation></Reference><Reference><Citation>ClinicalTrials.gov  Efficacy of Montelukast in Mild-Moderate Respiratory Symptoms in Patients with Long-COVID-19: (E-SPERANZA)  [(accessed on 14 February 2022)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT04695704.</Citation></Reference><Reference><Citation>ClinicalTrials.gov  Pilot Study Into LDN and NAD+ for Treatment of Patients with Post-COVID-19 Syndrome.  [(accessed on 14 February 2022)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT04604704.</Citation></Reference><Reference><Citation>ClinicalTrials.gov  Feasibility Pilot Clinical Trial of Omega-3 Supplement vs. Placebo for Post COVID-19 Recovery Among Health Care Workers.  [(accessed on 14 February 2022)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT05121766.</Citation></Reference><Reference><Citation>ClinicalTrials.gov  HElping Alleviate the Longer-Term Consequences of COVID-19 (HEAL-COVID)  [(accessed on 14 February 2022)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT04801940.</Citation></Reference><Reference><Citation>ClinicalTrials.gov  A Randomised-Controlled Trial of an Oral Microbiome Immunity Formula in Recovered COVID-19 Patients.  [(accessed on 14 February 2022)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT04950803.</Citation></Reference><Reference><Citation>ClinicalTrials.gov  COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)  [(accessed on 14 February 2022)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT04510194.</Citation></Reference><Reference><Citation>ClinicalTrials.gov  LYT-100 in Post-Acute COVID-19 Respiratory Disease.  [(accessed on 14 February 2022)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT04652518.</Citation></Reference><Reference><Citation>ClinicalTrials.gov  Vortioxetine for Post-COVID-19 Syndrome.  [(accessed on 14 February 2022)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT05047952.</Citation></Reference><Reference><Citation>ClinicalTrials.gov  Coenzyme Q10 as Treatment for Long Term COVID-19.  [(accessed on 14 February 2022)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT04960215.</Citation></Reference><Reference><Citation>ClinicalTrials.gov  Special Chinese Medicine Out-Patient Programme for Discharged COVID-19 Patients.  [(accessed on 14 February 2022)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT0444605.</Citation></Reference><Reference><Citation>ClinicalTrials.gov  Spironolactone and Dexamethasone in Patients Hospitalized With COVID-19 (SPIDEX-II)  [(accessed on 14 February 2022)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT04826822.</Citation></Reference><Reference><Citation>ClinicalTrials.gov  The Effect of Micellized Food Supplements on Health-related Quality of Life in Patients With Post-Acute COVID-19 Syndrome.  [(accessed on 14 February 2022)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT05150782.</Citation></Reference><Reference><Citation>ClinicalTrials.gov  Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19 (PEP-CQ)  [(accessed on 14 February 2022)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT04408456.</Citation></Reference><Reference><Citation>ClinicalTrials.gov  CACOLAC: Citrulline Administration in the Hospital Patient in Intensive Care for COVID-19 Acute Respiratory Distress Syndrome.  [(accessed on 14 February 2022)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT04404426.</Citation></Reference><Reference><Citation>ClinicalTrials.gov  Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2.  [(accessed on 14 February 2022)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT04846010.</Citation></Reference><Reference><Citation>ClinicalTrials.gov  Efficacy, Safety, Tolerability of AXA1125 in Fatigue Predominant PASC.  [(accessed on 14 February 2022)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT05152849.</Citation></Reference><Reference><Citation>ClinicalTrials.gov  Evaluation of the Effect of Long-Term Lipid-Lowering Therapy in STEMI Patients with Coronavirus Infection COVID-19.  [(accessed on 14 February 2022)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT04900155.</Citation></Reference><Reference><Citation>Post COVID-19 Syndrome and the Gut-Lung Axis.  [(accessed on 14 February 2022)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT04813718.</Citation></Reference><Reference><Citation>ClinicalTrials.gov  A Study of Immune System Proteins in Participants with Mild to Moderate COVID-19 Illness.  [(accessed on 14 February 2022)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT04634409.</Citation></Reference><Reference><Citation>ClinicalTrials.gov  Efficacy Evaluation of Shen Cao Gan Jiang Tang on Mild and Moderate COVID-19 Patients.  [(accessed on 14 February 2022)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT05055427.</Citation></Reference><Reference><Citation>Li L., Gou C.Y., Li X.M., Song W.Y., Wang X.J., Li H.Y., Li H.Y., Li X.H. Effects of Chinese Medicine on Symptoms, Syndrome Evolution, and Lung Inflammation Absorption in COVID-19 Convalescent Patients during 84-Day Follow-up after Hospital Discharge: A Prospective Cohort and Nested Case-Control Study. Chin. J. Integr. Med. 2021;27:245&#x2013;251. doi: 10.1007/s11655-021-3328-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11655-021-3328-3</ArticleId><ArticleId IdType="pmc">PMC7857094</ArticleId><ArticleId IdType="pubmed">33534076</ArticleId></ArticleIdList></Reference><Reference><Citation>May B.C., Gallivan K.H. Levocetirizine and montelukast in the COVID-19 treatment paradigm. Int. Immunopharmacol. 2022;103:108412. doi: 10.1016/j.intimp.2021.108412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2021.108412</ArticleId><ArticleId IdType="pmc">PMC8673734</ArticleId><ArticleId IdType="pubmed">34942461</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordero F.M., Monne S.B., Ortega J.A., Garc&#xed;a-Sangen&#xed;s A., Pu&#xe8;rtolas O.C., Contreras-Martos S., Mu&#xf1;oz G.A., Escol&#xe0; R.M., Jou&#xe9; M.B., Pedr&#xf3;s R.M., et al. Double-blind placebo-controlled randomized clinical trial to assess the efficacy of montelukast in mild to moderate respiratory symptoms of patients with long COVID: E-SPERANZA COVID Project study protocol. Trials. 2022;23:19. doi: 10.1186/s13063-021-05951-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-021-05951-w</ArticleId><ArticleId IdType="pmc">PMC8733792</ArticleId><ArticleId IdType="pubmed">34991703</ArticleId></ArticleIdList></Reference><Reference><Citation>Narimanian M., Badalyan M., Panosyan V., Gabrielyan E., Panossian A., Wikman G., Wagner H. Impact of Chisan (ADAPT-232) on the quality-of-life and its efficacy as an adjuvant in the treatment of acute non-specific pneumonia. Phytomedicine. 2005;12:723&#x2013;729. doi: 10.1016/j.phymed.2004.11.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phymed.2004.11.004</ArticleId><ArticleId IdType="pubmed">16323290</ArticleId></ArticleIdList></Reference><Reference><Citation>Aslanyan G., Amroyan E., Gabrielyan E., Panossian A., Wikman G. Double-blind, placebo-controlled, randomized study of the single-dose effects of ADAPT-232 on cognitive functions. Phytomedicine. 2010;17:494&#x2013;499. doi: 10.1016/j.phymed.2010.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phymed.2010.02.005</ArticleId><ArticleId IdType="pubmed">20374974</ArticleId></ArticleIdList></Reference><Reference><Citation>Hovhannisyan A., Nylander M., Wikman G., Panossian A.G. Efficacy of Adaptogenic Supplements on Adapting to Stress: A Randomized, Controlled Trial. J. Athl. Enhanc. 2015;19:2. doi: 10.4172/2324-9080.1000205.</Citation><ArticleIdList><ArticleId IdType="doi">10.4172/2324-9080.1000205</ArticleId></ArticleIdList></Reference><Reference><Citation>Panossian A., Wikman G. Evidence-based efficacy of adaptogens in fatigue, and molecular mechanisms related to their stress-protective activity. Current Clin. Pharmacol. 2009;4:198&#x2013;219. doi: 10.2174/157488409789375311.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/157488409789375311</ArticleId><ArticleId IdType="pubmed">19500070</ArticleId></ArticleIdList></Reference><Reference><Citation>Panossian A., Hamm R., Kadioglu O., Wikman G., Efferth T. Synergy and Antagonism of Active Constituents of ADAPT-232 on Transcriptional Level of Metabolic Regulation of Isolated Neuroglial Cells. Front. Neurosci. 2013;7:16. doi: 10.3389/fnins.2013.00016.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2013.00016</ArticleId><ArticleId IdType="pmc">PMC3576868</ArticleId><ArticleId IdType="pubmed">23430930</ArticleId></ArticleIdList></Reference><Reference><Citation>Panossian A., Brendler T. The Role of Adaptogens in Prophylaxis and Treatment of Viral Respiratory Infections. Pharmaceuticals. 2020;13:236. doi: 10.3390/ph13090236.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph13090236</ArticleId><ArticleId IdType="pmc">PMC7558817</ArticleId><ArticleId IdType="pubmed">32911682</ArticleId></ArticleIdList></Reference><Reference><Citation>Said E.A., Al-Reesi I., Al-Shizawi N., Jaju S., Al-Balushi M.S., Koh C.Y., Al-Jabri A.A., Jeyaseelan L. Defining IL-6 levels in healthy individuals: A meta-analysis. J. Med. Virol. 2021;93:3915&#x2013;3924. doi: 10.1002/jmv.26654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26654</ArticleId><ArticleId IdType="pubmed">33155686</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Hao Y., Ou W., Ming F., Liang G., Qian Y., Cai Q., Dong S., Hu S., Wang W., et al. Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: A cohort study. J. Transl. Med. 2020;18:406. doi: 10.1186/s12967-020-02571-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-020-02571-x</ArticleId><ArticleId IdType="pmc">PMC7594951</ArticleId><ArticleId IdType="pubmed">33121497</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabaka P., Ko&#x161;&#x10d;&#xe1;lov&#xe1; A., Straka I., Hodosy J., Lipt&#xe1;k R., Kmotorkov&#xe1; B., Kachl&#xed;kov&#xe1; M., Ku&#x161;n&#xed;rov&#xe1; A. Role of interleukin 6 as a predictive factor for a severe course of COVID-19: Retrospective data analysis of patients from a long-term care facility during COVID-19 outbreak. BMC Infect. Dis. 2021;21:308. doi: 10.1186/s12879-021-05945-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-021-05945-8</ArticleId><ArticleId IdType="pmc">PMC8006112</ArticleId><ArticleId IdType="pubmed">33781216</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonnweber T., Boehm A., Sahanic S., Pizzini A., Aichner M., Sonnweber B., Kurz K., Koppelst&#xe4;tter S., Haschka D., Petzer V., et al. Persisting alterations of iron homeostasis in COVID-19 are associated with non-resolving lung pathologies and poor patients&#x2019; performance: A prospective observational cohort study. Respir. Res. 2020;21:276. doi: 10.1186/s12931-020-01546-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-020-01546-2</ArticleId><ArticleId IdType="pmc">PMC7575703</ArticleId><ArticleId IdType="pubmed">33087116</ArticleId></ArticleIdList></Reference><Reference><Citation>Cione E., Siniscalchi A., Gangemi P., Cosco L., Colosimo M., Longhini F., Luciani F., De Sarro G., G&amp;SPWorking Group Berrino L., D&#x2019;Agostino B., et al. Neuron-specific enolase serum levels in COVID-19 are related to the severity of lung injury. PLoS ONE. 2021;16:e0251819. doi: 10.1371/journal.pone.0251819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0251819</ArticleId><ArticleId IdType="pmc">PMC8133450</ArticleId><ArticleId IdType="pubmed">34010310</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe B., Xie Y., Xu E., Al-Aly Z. Kidney Outcomes in Long COVID.  [(accessed on 14 February 2022)];J. Am. Soc. Nephrol. 2021 32:2851&#x2013;2862. doi: 10.1681/ASN.2021060734. Available online:  https://jasn.asnjournals.org/content/early/2021/08/25/ASN.2021060734.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2021060734</ArticleId><ArticleId IdType="pmc">PMC8806085</ArticleId><ArticleId IdType="pubmed">34470828</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#x142;owacka M., Lipka S., M&#x142;ynarska E., Franczyk B., Rysz J. Acute Kidney Injury in COVID-19. Int. J. Mol. Sci. 2021;22:8081. doi: 10.3390/ijms22158081.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22158081</ArticleId><ArticleId IdType="pmc">PMC8347536</ArticleId><ArticleId IdType="pubmed">34360866</ArticleId></ArticleIdList></Reference><Reference><Citation>Yende S., Parikh C.R. Long COVID and kidney disease. Nat. Rev. Nephrol. 2021;17:792&#x2013;793. doi: 10.1038/s41581-021-00487-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41581-021-00487-3</ArticleId><ArticleId IdType="pmc">PMC8427150</ArticleId><ArticleId IdType="pubmed">34504319</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang N.H., Cheng Y.C., Luo R., Zhang C.X., Ge S.W., Xu G. Recovery of new-onset kidney disease in COVID-19 patients discharged from hospital. BMC Infect. Dis. 2021;21:397. doi: 10.1186/s12879-021-06105-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-021-06105-8</ArticleId><ArticleId IdType="pmc">PMC8083091</ArticleId><ArticleId IdType="pubmed">33926392</ArticleId></ArticleIdList></Reference><Reference><Citation>Panossian A.G., Efferth T., Shikov A.N., Pozharitskaya O.N., Kuchta K., Mukherjee P.K., Banerjee S., Heinrich M., Wu W., Guo D.A., et al. Evolution of the adaptogenic concept from traditional use to medical systems: Pharmacology of stress- and aging-related diseases. Med. Res. Rev. 2021;41:630&#x2013;703. doi: 10.1002/med.21743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21743</ArticleId><ArticleId IdType="pmc">PMC7756641</ArticleId><ArticleId IdType="pubmed">33103257</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>